NEWS
Essity mulls selling Vinda stake and Consumer Tissue Private Label Europe business
Essity mulls selling Vinda stake and Consumer Tissue Private Label Europe business
STOCKHOLM (Reuters) – Hygiene products group Essity said on Wednesday it has initiated a strategic review of its stake in China-based Vinda and its Consumer Tissue Private Label Europe business.
The Swedish company said in a statement the aim of the review is to reduce its Consumer Tissue division’s share of group sales.
“The strategic review includes exploring different options and may result in divestments, although no such decisions have yet been taken,” it said.
Essity is the majority shareholder in Hong Kong-based Vinda with a 52% stake.
Vinda in 2022 accounted for 16% of Essity’s 156 billion Swedish crowns ($15.16 billion) turnover, while the Consumer Tissue Private Label Europe business represented 6%.
($1 = 10.2929 Swedish crowns)
(Reporting by Anna Ringstrom, editing by Terje Solsvik)
-
FINANCE3 days ago
WhisperClaims urges accountants to keep calm and carry on despite reforms to the R&D tax industry
-
NEWS3 days ago
Richard Teng seen as potential successor to Binance’s Changpeng Zhao -reports
-
NEWS3 days ago
UK auto industry body says new car sales rise in May, but below pre-COVID level
-
NEWS3 days ago
Euro zone business growth slowed in May as factories struggled-PMI